Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- (-) Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 146 Results
New Study Reveals Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
When the health care community talks about evidence-based medicine, it’s usually in the context of efforts to ensure clinicians are delivering treatments to patients that align with the best…
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
Second National Pharmaceutical Council and Health Affairs Forum to Explore Emerging Health Spending Solutions
NPC, Health Affairs and several Going Below The Surface Forum partners on Sept. 11 are hosting a discussion among health policy experts on emerging solutions to rising U.S. health spending
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
Six Ways to Make Real-world Evidence Methods More Transparent
Acceptance of studies based on “real-world data” remains limited, partly because the research methods used to generate usable evidence are not always transparent. That perception could change thanks…
NPC in Chain Drug Review: The Long-term Health Benefits of Biopharmaceuticals
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care…
Tackling Low-Value Care Will Take a Group Effort
During a briefing with partners of the Going Below The Surface Forum, three leaders in the effort to reduce low-value care in the United States explained why this has been such a tough challenge to…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
Paying for Cures: Ensuring Patient Access and System Sustainability
One of the most vexing challenges facing the U.S. health care system is how payers and biopharmaceutical innovators can work together to ensure that curative treatments are more broadly accessible to…
NPC in Specialty Pharmacy Times: How Can We Advance Progress in Moving from Volume to Value in Health Care?
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a…
Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust
Researchers found that while most patient organizations were initially unaware of real-world evidence (RWE) and its actual or potential uses, they recognized the ability of RWE to provide relevant…
Patients on RWE: WIIFM? (What’s In It for Me?)
In an article published in The Patient, NPC and the National Health Council found that while most patients were initially unaware of real-world evidence (RWE) and its actual or potential uses,…
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…
Study Finds That Costs Dropped, Outcomes Improved for Major Causes of Death and Illness Between 1995 and 2015
Spending for six of the top seven causes of death and disease over the last 20 years was both cost-effective and improved patient outcomes, according to a study from NPC and RTI Health Solutions…
NPC in Chain Drug Review: Preserving the Proven Impact of Biopharmaceutical Innovation
In his latest commentary for Chain Drug Review, NPC President and Chief Executive Officer Dan Leonard considers the challenges in measuring and paying for value in health care, particularly when it…
Get to Know Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD
Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD, sat down with us to discuss her upcoming research, bridging the gap between academia and health care stakeholders, tips for…